Your browser doesn't support javascript.
loading
Outcomes after endoscopic local excision of early-stage gastric adenocarcinoma in the United States.
Newland, John J; Johnson, Abree M; Feng, Zhaoyong; Kim, Raymond E; Williams, Richelle T; Hanna, Nader N; Mullins, C Daniel; Hu, Yinin.
Afiliação
  • Newland JJ; University of Maryland Medical Center, Department of General Surgery, USA.
  • Johnson AM; University of Maryland Baltimore, Department of Pharmaceutical Health Services Research, USA; Maryland Surgery, Pharmacy, and Anesthesiology Research Collaborative, USA.
  • Feng Z; University of Maryland Baltimore, Department of Pharmaceutical Health Services Research, USA; Maryland Surgery, Pharmacy, and Anesthesiology Research Collaborative, USA.
  • Kim RE; University of Maryland Medical Center, Department of Gastroenterology, USA.
  • Williams RT; University of Maryland Medical Center, Department of General Surgery, USA; Maryland Surgery, Pharmacy, and Anesthesiology Research Collaborative, USA.
  • Hanna NN; University of Maryland Medical Center, Department of General Surgery, USA.
  • Mullins CD; University of Maryland Baltimore, Department of Pharmaceutical Health Services Research, USA; Maryland Surgery, Pharmacy, and Anesthesiology Research Collaborative, USA.
  • Hu Y; University of Maryland Medical Center, Department of General Surgery, USA; Maryland Surgery, Pharmacy, and Anesthesiology Research Collaborative, USA. Electronic address: yinin.hu@som.umaryland.edu.
Surg Oncol ; 48: 101937, 2023 Jun.
Article em En | MEDLINE | ID: mdl-37058972
ABSTRACT
BACKGROUND AND

OBJECTIVES:

Local excision (LE) for early-stage gastric cancer has expanded in the United States over recent years, however, national outcomes are unknown. The objective of the study was to evaluate national survival outcomes following LE for early-stage gastric cancer.

METHODS:

Patients with resectable gastric adenocarcinoma between 2010 and 2016 were identified from the National Cancer Database then classified by LE curability into eCuraA (high) and eCuraC (low) according to Japanese Gastric Cancer Association guidelines. Demographics, clinical/provider descriptors, and perioperative/survival outcomes were extracted. Propensity-weighted cox proportional hazards regression assessed factors associated with overall survival.

RESULTS:

Patients were stratified into eCuraA (N = 1167) and eCuraC (N = 13,905) subgroups. Postoperative 30-day mortality (0% vs 2.8%, p < 0.001) and readmission (2.3% vs 7.8%, p = 0.005) favored LE. Local excision was not associated with survival on propensity-weighted analyses. However, among eCuraC patients, LE was associated with higher likelihood of positive margins (27.1% vs 7.0%, p < 0.001), which was the strongest predictor of poor survival (HR 2.0, p < 0.001).

CONCLUSIONS:

Although early morbidity is low, oncologic outcomes following LE are compromised for eCuraC patients. These findings support careful patient selection and treatment centralization in the early adoption phase of LE for gastric cancer.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Retais / Neoplasias Gástricas / Procedimentos Cirúrgicos do Sistema Digestório / Adenocarcinoma Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Retais / Neoplasias Gástricas / Procedimentos Cirúrgicos do Sistema Digestório / Adenocarcinoma Idioma: En Ano de publicação: 2023 Tipo de documento: Article